Key Events This Week
2 Mar: Stock plunged to lower circuit amid heavy selling pressure
5 Mar: Surged to upper circuit on strong buying interest
6 Mar: Hit upper circuit again, closing with a 3.94% gain
Weekly Close: Rs.7.13, down 6.55% for the week
2 March 2026: Sharp Decline to Lower Circuit Amid Heavy Selling
Vivimed Labs Ltd opened the week under intense selling pressure, plunging to its lower circuit limit on 2 March 2026. The stock closed at Rs.7.25, down 4.98% on the day, significantly underperforming the Sensex which fell 1.41%. Intraday, the stock touched a low of Rs.7.20, reflecting panic selling and a sharp drop in investor participation.
The micro-cap pharmaceutical company’s volume was subdued at 4,712 shares, with delivery volumes down over 40% compared to the recent average, signalling waning conviction among long-term holders. The stock traded below all key moving averages, reinforcing a bearish technical outlook. This steep decline and circuit hit underscored the fragile sentiment surrounding Vivimed Labs amid sectoral headwinds and company-specific challenges.
4 March 2026: Continued Weakness on Low Liquidity
Trading resumed on 4 March after a holiday, with Vivimed Labs continuing its downward trajectory. The stock closed at Rs.7.01, down 3.31%, further underperforming the Sensex’s 1.92% decline. Volume surged to 17,199 shares, yet delivery volumes remained sharply lower, down 45.44% from the five-day average, indicating persistent investor caution. The stock’s decline despite increased volume suggested that selling pressure remained dominant, with no significant buying support emerging.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
5 March 2026: Upper Circuit Triggered on Strong Buying Interest
In a notable reversal, Vivimed Labs surged on 5 March 2026, hitting its upper circuit limit with a 2.6% intraday gain and closing at Rs.7.03. This rally occurred despite the stock’s recent downgrade to a Strong Sell rating and its position below all major moving averages. The stock outperformed the Sensex, which rose 1.29%, and the pharmaceutical sector, which gained 1.45%.
Trading volume increased to 25,585 shares, reflecting moderate liquidity and a surge in buying demand. However, delivery volumes remained depressed, down 71% compared to the five-day average, suggesting that much of the buying was speculative or intraday in nature. The upper circuit hit imposed a regulatory freeze on further price gains for the day, highlighting the imbalance between demand and supply.
6 March 2026: Sustained Buying Pushes Stock to Upper Circuit Again
Vivimed Labs continued its momentum on 6 March 2026, hitting the upper circuit limit once more and closing at Rs.7.13, up 1.42% on the day. The stock outperformed the Sensex, which declined 0.98%, and the pharmaceutical sector, which gained a modest 0.36%. Total traded volume was 20,569 shares, with turnover of approximately Rs.0.07 crore.
Despite this short-term strength, the stock remains below all key moving averages, indicating that the rally is occurring from a technically weak base. Delivery volumes remained low, reinforcing concerns that the recent buying may lack long-term conviction. The regulatory freeze triggered by the upper circuit hit may lead to volatile price action in subsequent sessions as unfilled demand is either executed or withdrawn.
Vivimed Labs Ltd or something better? Our SwitchER feature analyzes this micro-cap stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Daily Price Performance vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-03-02 | Rs.7.25 | -4.98% | 35,812.02 | -1.41% |
| 2026-03-04 | Rs.7.01 | -3.31% | 35,125.64 | -1.92% |
| 2026-03-05 | Rs.7.03 | +0.29% | 35,579.03 | +1.29% |
| 2026-03-06 | Rs.7.13 | +1.42% | 35,232.05 | -0.98% |
Key Takeaways
The week for Vivimed Labs Ltd was marked by significant volatility, with the stock experiencing both lower and upper circuit hits within days. The initial sharp decline on 2 March reflected intense selling pressure and weak investor confidence, exacerbated by the stock trading below all major moving averages and a Strong Sell Mojo Grade of 14.0.
The subsequent rallies on 5 and 6 March, which triggered upper circuit limits, indicate pockets of strong buying interest, possibly speculative in nature given the persistently low delivery volumes. These short-term surges outperformed the Sensex and the pharmaceutical sector on their respective days but have yet to translate into a sustained recovery.
Liquidity remains moderate for a micro-cap stock, with trading volumes fluctuating but delivery volumes consistently declining, suggesting limited long-term holding conviction. The regulatory freezes triggered by circuit hits may lead to heightened volatility in coming sessions as unfilled demand is addressed.
Overall, the stock’s technical weakness, combined with its Strong Sell rating and micro-cap status, signals elevated risk. Investors should remain cautious and monitor upcoming trading sessions closely for confirmation of any sustained trend reversal or further deterioration.
Conclusion
Vivimed Labs Ltd’s week was characterised by sharp swings and circuit-triggered trading halts, reflecting a micro-cap stock grappling with weak fundamentals and volatile market sentiment. While the upper circuit hits on 5 and 6 March demonstrate renewed buying interest, the underlying technical and fundamental indicators remain bearish. The stock’s 6.55% weekly decline, outpacing the Sensex’s 3.00% fall, underscores the challenges faced by investors in this counter.
Given the persistent low delivery volumes and the Strong Sell Mojo Grade, the recent rallies should be viewed with caution. Market participants are advised to watch for sustained momentum or signs of profit-taking in the near term before considering exposure to Vivimed Labs Ltd.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
